A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

NCT07190833 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment-Refractory Solid Tumors

Interventions

DRUG: OTS-412
DRUG: Hydroxyurea (HU)
DRUG: Hydroxyurea (HU)
DRUG: Hydroxyurea (HU)
DRUG: Hydroxyurea (HU)
DRUG: Atezolizumab
DRUG: OTS-412
DRUG: OTS-412

Sponsor

Bionoxx Inc.